New partnership: Xilaplus® AF in Turkey

New partnership: Xilaplus® AF in Turkey

Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey.

Xilaplus® AF is a Class IIa CE marked medical device specifically formulated for the control and reduction of diarrheal events of various etiologies. Xilaplus® AF acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhoea episodes and associated symptoms in adults, children, and infants.

This is a fantastic opportunity for both companies, considering the size of the Turkish antidiarrheals market and the innovation that Xilaplus® AF brings. We look forward to this exciting joint project.